Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06541730
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
A Study Evulating DA-302168S Tablets in OverweightObese Subjects
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase Ic Clinical Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of DA-302168S Tablets in OverweightObese Subjects After Multiple Oral Administration
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DA168
Brief Summary:
The goal of this clinical trial is to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweightobese subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None